Effect of selenium supplementation on glutathione peroxidase enzyme activity in patients with chronic kidney disease

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201305318501N2

Enrollment

Registered

2013-06-29

Start date

2012-12-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease. Chronic kidney disease

Interventions

selenium tablet (Nature Made product, made in USA) 200 microgram/day for 3 months to all patients.

Treatment - Drugs

selenium tablet (Nature Made product, made in USA) 200 microgram/day for 3 months to all patients

Eligibility

Sex/Gender

All

Age

20 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1) Patient with chronic kidney disease for = 3 month 2) patients= 20 years and<65 years3) Plasma albumin level 4 g/dl Exclusion criteria:1) Acute infection 2) Recent acute myocardial infarction during 6 week ago 3) Recent consumption of antioxidant drugs (for example vitamine A, E, C) 4) Active smoking 5) History of new or old cancer 6)Liver failure

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Glutathione peroxidase enzyme activity. Timepoint: Before study, Three months after drug supplementation. Method of measurement: ELISA (Kit made by UK).	—

Secondary

Measure	Time frame
Selenium plasma level. Timepoint: Before study, Three months after drug supplementation. Method of measurement: Electrothermal atomic absorbtion spectrometry(ETAAS).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactOmid Sedighi

Mazandaran University of Medical Sciences

omid_sadighi2007@yahoo.com+98 15 1311 5225

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Mar 20, 2026